Supplemental Table 1. Terms from OCI developed for Clinical Trail Ontology

Terms	Included in CDISC*	P-value One sided (ALL)	P-value < 0.074*	Included in CDISC and signficant p-value*
ADVERSE EVENT	1	0.00	1	1
ASSESSMENT	1	0.00	1	1
BASELINE	1	0.00	1	1
CIP	1	0.00	1	1
COHORT	1	0.00	1	1
COMPLIANCE	1	0.00	1	1
CONFIDENCE INTERVAL	1	0.00	1	1
COST	0	0.00	1	0
DATABASE	0	0.00	1	0
DATE	0	0.00	1	0
DRUG	1	0.00	1	1
DURATION	0	0.00	1	0
EC	0	0.00	1	0
EFFICACY	1	0.00	1	1
ELIGIBILITY	0	0.00	1	0
ENDPOINT	1	0.00	1	1
EVALUATION	1	0.00	1	1
EVENT	0	0.00	1	0
FDA	1	0.00	1	1
FOLLOW-UP	0	0.00	1	0
INCLUSION CRITERIA	1	0.00	1	1
INTERVAL	0	0.00	1	0
INTERVENTION	1	0.00	1	1
INVESTIGATOR	1	0.00	1	1
MEDICATION	0	0.00	1	0
META-ANALYSIS	1	0.00	1	1
OUTCOME	1	0.00	1	1
PATIENT	1	0.00	1	1
PHASE I TRIAL	1	0.00	1	1
PHASE II TRIAL	1	0.00	1	1
PHASE III TRIAL	1	0.00	1	1
PLACEBO	1	0.00	1	1
PRIMARY OUTCOME	0	0.00	1	0
PROTOCOL	1	0.00	1	1
PUBLICATION	0	0.00	1	0
RESPONSE	0	0.00	1	0
SAFETY	1	0.00	1	1
SAMPLE SIZE	1	0.00	1	1
SIDE-EFFECT	1	0.00	1	1
SPONSOR	1	0.00	1	1
SUBGROUP	0	0.00	1	0
THERAPY	0	0.00	1	0
TREATMENT	0	0.00	1	0
TRIAL	0	0.00	1	0
MONITORING	1	0.00	1	1
BLINDING	1	0.00	1	1

INFORMED CONSENT	1	0.00	1	1
MONITOR	1	0.00	1	1
TRIAL REPORT	0	0.00	1	0
BIAS	1	0.00	1	1
SERIOUS ADVERSE EVENT	1	0.00	1	1
PROGNOSTIC FACTOR	0	0.00	1	0
SURROGATE MARKER	1	0.00	1	1
DEVICE	0	0.00	1	0
STRATIFICATION	1	0.00	1	1
EXCLUSION CRITERIA	1	0.00	1	1
CCI	0	0.00	1	0
POPULATION	1	0.00	1	1
PREVENTION TRIALS	0	0.00	1	0
INTERIM ANALYSIS	1	0.00	1	1
INSTITUTION	1	0.00	1	1
POWER	0	0.00	1	0
GROUP SEQUENTIAL	1	0.00	1	1
CONTROL GROUP	1	0.00	1	1
MISSING DATA	1	0.00	1	1
VARIABLE	1	0.00	1	1
STUDY GROUP	0	0.00	1	0
DROPOUT	1	0.00	1	1
SUBJECT	0	0.00	1	0
CLINICAL STUDY	1	0.00	1	1
ANTIBIOTIC	0	0.00	1	0
DDS	0	0.00	1	0
REFERENCE	0	0.00	1	0
CONTEXT	0	0.00	1	0
CROSSOVER	0	0.00	1	0
QUESTIONNAIRE	1	0.00	1	1
ADHERENCE	0	0.00	1	0
RECRUITMENT	1	0.00	1	1
OBSERVATION	1	0.00	1	1
TYPE I ERROR	1	0.00	1	1
ESTIMATE	0	0.00	1	0
NEW DRUG APPLICATION	1	0.00	1	1
VITAMIN	0	0.00	1	0
ETHICS	0	0.00	1	0
MONITORING COMMITTEE	1	0.00	1	1
DICHOTOMOUS	0	0.00	1	0
GROWTH FACTOR	0	0.00	1	0
TREATED GROUP	0	0.00	1	0
LOCAL CONTROL	0	0.00	1	0
STUDY POPULATION	1	0.00	1	1
TREATMENT ALLOCATION	0	0.00	1	0
INSTRUMENT	1	0.00	1	1
POOL	0	0.00	1	0
ADJUSTMENT	0	0.00	1	0
SEQUENTIAL DESIGN	0	0.00	1	0
PRINCIPAL INVESTIGATOR	0	0.00	1	0
DROPOUTS	1	0.00	1	1

NULL HYPOTHESIS	1	0.00	1	1
ETHICS COMMITTEE	1	0.00	1	1
VOLUNTEER	1	0.00	1	1
INSTITUTIONAL REVIEW BOARD	1	0.00	1	1
CENSORING	0	0.00	1	0
EARLY TERMINATION	0	0.00	1	0
IND	0	0.00	1	0
SELECTION BIAS	0	0.00	1	0
EQUIPOISE	1	0.00	1	1
SURROGATE OUTCOME	0	0.00	1	0
DATA MANAGEMENT	1	0.00	1	1
CASE REPORT FORM	1	0.00	1	1
ACTIVE CONTROL	0	0.00	1	0
BLOCK	0	0.00	1	0
TYPE II ERROR	1	0.00	1	1
PROCEDURE	0	0.00	1	0
ACCRUAL RATE	0	0.00	1	0
PIVOTAL TRIALS	0	0.00	1	0
INVESTIGATIONAL NEW DRUG APPLICATION	0	0.00	1	0
PROTOCOL VIOLATION	0	0.00	1	0
PATIENT-REPORTED OUTCOME	1	0.00	1	1
VARIABILITY	0	0.00	1	0
WASHOUT PERIOD	1	0.00	1	1
QUALITY ASSURANCE	1	0.00	1	1
CONSENT FORM	1	0.00	1	1
DOUBLE BLINDING	1	0.00	1	1
CLINICAL LABORATORY	0	0.00	1	0
MULTIVARIABLE	0	0.00	1	0
P-VALUE	1	0.00	1	1
PROGENITOR	0	0.00	1	0
SPECIAL POPULATION	1	0.00	1	1
SCREENING	1	0.00	1	1
CONSORT STATEMENT	0	0.00	1	0
NONINFERIORITY	0	0.00	1	0
PACKAGE INSERT	0	0.00	1	0
FACTORIAL DESIGN	0	0.00	1	0
NONCOMPLIANCE	0	0.00	1	0
NUTRITIONAL SUPPLEMENT	0	0.00	1	0
SIRE	0	0.00	1	0
EQUIVALENCE TRIALS	1	0.00	1	1
CONFIRMATORY TRIAL	1	0.00	1	1
DATA SAFETY MONITORING COMMITTEE	0	0.00	1	0
EUROPEAN MEDICINES AGENCY	1	0.00	1	1
TRIAL SITE	1	0.00	1	1
NONADHERENCE	0	0.00	1	0
DOSE FINDING	0	0.00	1	0
CROSSOVER TRIAL	1	0.00	1	1
CLINICAL RESEARCH COORDINATOR	1	0.00	1	1
NO-TREATMENT	0	0.00	1	0
STEERING COMMITTEE	0	0.00	1	0
CRC	0	0.00	1	0

MEDICAL DEVICE	0	0.00	1	0
STUDY COORDINATOR	1	0.00	1	1
CLINICAL RESEARCH ASSOCIATE	1	0.00	1	1
INVESTIGATIONAL PRODUCT	1	0.00	1	1
APPROVABLE LETTER	1	0.00	1	1
EMEA	0	0.00	1	0
CONTRACT RESEARCH ORGANIZATION	0	0.00	1	0
CV	0	0.00	1	0
TIMEPOINT	0	0.00	1	0
CONFOUNDER	0	0.00	1	0
HEALTHCARE PROVIDER	1	0.00	1	1
COINTERVENTION	0	0.00	1	0
DRUG PRODUCT	0	0.00	1	0
SOURCE DOCUMENT	1	0.00	1	1
PER-PROTOCOL POPULATION	1	0.00	1	1
CONFOUNDING FACTOR	0	0.00	1	0
CONCURRENT CONTROLS	0	0.00	1	0
ONE-SIDED TEST	0	0.00	1	0
ALTERNATIVE HYPOTHESIS	0	0.00	1	0
URN RANDOMIZATION	0	0.00	1	0
ELECTRONIC DATA CAPTURE	1	0.00	1	1
MONITORING REPORT	1	0.00	1	1
CASE REPORT	1	0.00	1	1
STATISTICAL ANALYSIS PLAN	1	0.00	1	1
PRIMARY VARIABLE	1	0.00	1	1
TWO-SIDED TEST	0	0.00	1	0
SHAM TREATMENT	0	0.00	1	0
ORIGINAL DATA	1	0.00	1	1
CARRYOVER EFFECT	1	0.00	1	1
HISTORIC CONTROLS	0	0.00	1	0
PROTOCOL AMENDMENT	1	0.00	1	1
POSITIVE FINDINGS	0	0.00	1	0
FINAL REPORT	0	0.00	1	0
ASSESSMENT BIAS	0	0.00	1	0
AUTHORSHIP	0	0.00	1	0
LOCAL RESEARCH ETHICS COMMITTEES	0	0.00	1	0
IRB	0	0.00	1	0
MHRA	0	0.00	1	0
ROLE	1	0.00	1	1
CLUSTER RANDOMIZATION	0	0.00	1	0
BASELINE COMPARABILITY	0	0.00	1	0
IMBALANCE	0	0.00	1	0
ALLOCATION RATIO	0	0.00	1	0
CLINICAL TRIAL EXEMPTION	1	0.00	1	1
RESEARCH ETHICS BOARD	0	0.00	1	0
FUNDER	0	0.00	1	0
RANDOMIZED POPULATION	0	0.00	1	0
AUDITING	1	0.00	1	1
PHASE IV TRIAL	1	0.00	1	1
ELIGIBLE POPULATION	0	0.00	1	0
AUDIT REPORT	1	0.00	1	1

NEGATIVE FINDINGS	0	0.00	1	0
STATISTICAL SIGNIFICANT	1	0.00	1	1
MINORITY REPRESENTATION	0	0.00	1	0
UNIVARIABLE	0	0.00	1	0
QUERY	1	0.00	1	1
PRIMARY-OUTCOME	1	0.00	1	1
OPTIMAL ALLOCATION	0	0.00	1	0
REPEAT MEASUREMENT	0	0.00	1	0
WARNING LETTER	1	0.00	1	1
FOOD AND DRUG ADMINISTRATION	1	0.00	1	1
COORDINATING COMMITTEE	1	0.00	1	1
AMENDMENT	1	0.00	1	1
INDEPENDENT ETHICS COMMITTEE	1	0.00	1	1
STUDY REPORT	0	0.00	1	0
RETROSPECTIVE DESIGN	1	0.00	1	1
BALANCED DESIGN	1	0.00	1	1
SURROGATE VARIABLE	1	0.00	1	1
LREC	0	0.00	1	0
ANALYSIS SET	1	0.00	1	1
CCPPRB	0	0.00	1	0
LEGALLY ACCEPTABLE REPRESENTATIVE	1	0.01	1	1
TRIAL-DESIGN	0	0.01	1	0
MAIN EFFECT	0	0.01	1	0
ANALYZED POPULATION	0	0.01	1	0
INTRASUBJECT	0	0.01	1	0
PROTOCOL EXCEPTION	0	0.01	1	0
INTENTION TO TREAT	1	0.01	1	1
NEYMAN ALLOCATION	0	0.01	1	0
TREATMENT-ASSIGNMENT	0	0.01	1	0
EXPERIMENT	0	0.01	1	0
METABOLITE	1	0.02	1	1
APPROVAL LETTER	1	0.02	1	1
INDEPENDENT REVIEW BOARD	0	0.02	1	0
ENROLLED POPULATION	1	0.02	1	1
MEDICAL MONITOR	1	0.02	1	1
EXCLUDED POPULATION	0	0.02	1	0
CSO	0	0.03	1	0
ASSESSMENT SCHEDULE	0	0.03	1	0
INTERNAL REVIEW BOARD	0	0.03	1	0
PERMUTED BLOCK RANDOMIZATION	0	0.04	1	0
DOUBLE MASKING	1	0.04	1	1
QC	1	0.04	1	1
NB	0	0.05	1	0
ANALYSIS VARIABLE	1	0.05	1	1
DATA COLLECTION SCHEDULE	1	0.05	1	1
SCREENED POPULATION	0	0.05	1	0
ACTION LETTER	0	0.06	1	0
DIAGNOSTIC TRIAL	0	0.06	1	0
PATIENT FILE	1	0.07	1	1
MREC	0	0.09	0	0
NUTRIENT	0	0.12	0	0

WITHDRAWAL CONSENT	1	0.12	0	0
NUMERIC DATA	0	0.14	0	0
EXECUTIVE COMMITTEE	0	0.16	0	0
PROJECT MANAGEMENT	0	0.16	0	0
DERIVED DATA	1	0.18	0	0
DATA OWNER	0	0.19	0	0
TEXTUAL DATA	0	0.20	0	0
ELECTRONIC SIGNATURE	1	0.22	0	0
POPULATION REPRESENTATIVE	0	0.22	0	0
CLINICAL DOCUMENT	1	0.22	0	0
ERRATUM	0	0.23	0	0
INTERSUBJECT	0	0.27	0	0
CASE-CONTROL DESIGN	0	0.28	0	0
RECRUITED POPULATION	0	0.29	0	0
VULNERABLE SUBJECT	1	0.31	0	0
ANTIBODY	0	0.32	0	0
MASKING	0	0.39	0	0
CONTACT PERSON	0	0.39	0	0
DOCUMENT ROLE	1	0.49	0	0
SUPPLIER	1	0.55	0	0
PATHOLOGIST	0	0.63	0	0
POSITIVE CONTROL	0	0.66	0	0
CRB	0	0.73	0	0
DAM	0	0.74	0	0
CONTINOUS	0	0.85	0	0
VITAL DYE	0	0.87	0	0
SURVEY	1	0.90	0	0
RANDOM SAMPLE	0	0.93	0	0
PSEUDORANDOM	0	0.94	0	0
ANTIGEN	0	0.97	0	0
DETERMINISTIC	0	0.99	0	0
CONSTRAIN	0	1.00	0	0
EPITOPE	0	1.00	0	0
NEGATIVE CONTROL	0	1.00	0	0
CASE HISTORY	1	1.00	0	0
STUDY ROLE	0	1.00	0	0
CHR	0	1.00	0	0
BLA	0	1.00	0	0
REB	0	1.00	0	0
CRA	0	1.00	0	0
REGULATORY ROLE	0	1.00	0	0
BEDDING	0	1.00	0	0
CODING	1	1.00	0	0
CONTRACT	0	1.00	0	0
CONTROL VALUE	0	1.00	0	0
CONTROLS	1	1.00	0	0
CULTURE MEDIUM	0	1.00	0	0
DISCRET	0	1.00	0	0
DYE	0	1.00	0	0
EAB	0	1.00	0	0
FEED	0	1.00	0	0

HEX	0	1.00	0	0
IEC	1	1.00	0	0
INTERACTION	1	1.00	0	0
LABEL	1	1.00	0	0
OFFSPRING	0	1.00	0	0
ORIGIN	0	1.00	0	0
PMA	1	1.00	0	0
REAGENT	0	1.00	0	0
REPORTER	0	1.00	0	0
SPECIMEN	0	1.00	0	0
STAIN	0	1.00	0	0
SUBSTRATE	0	1.00	0	0
TOME	1	1.00	0	0
COMPARATOR	1	1.0e-312	0	0
REASON	0	1.34e-319	0	0

* 1=Yes 0=No